

1 **Title: SARS-CoV-2 variants of concern Alpha and Delta show increased viral load in**
2 **saliva**

3
4 **Authors:** Kylie L. King¹, Stevin Wilson², Justin M. Napolitano¹, Keegan J. Sell¹, Lior Rennert³,
5 Christopher L. Parkinson^{2,4}, Delphine Dean^{1,5}.

6
7
8 **Affiliations:**

9 ¹Center for Innovative Medical Devices and Sensors (REDDI Lab), Clemson University,
10 Clemson, South Carolina, United States of America.

11 ²Clemson University Genomics and Bioinformatics Facility, Clemson, South Carolina, United
12 States of America.

13 ³Department of Public Health Sciences, Clemson University, Clemson, South Carolina, United
14 States of America.

15 ⁴Department of Biological Sciences and Department of Forestry and Environmental
16 Conservation, Clemson University, Clemson, South Carolina, United State of America

17 ⁵Department of Bioengineering, Clemson University, Clemson, South Carolina, United States of
18 America.

19
20 **Short Title:** Viral Load of SARS-COV-2 Variants

21
22 **Corresponding Author:** Delphine Dean, 864-656-2611, finou@clemson.edu

23
24
25

26 **Abstract:**

27 **Background**

28 Higher viral loads in SARS-CoV-2 infections may be linked to more rapid spread of emerging
29 Variants of Concern. Rapid detection and isolation of cases with highest viral loads, even in pre-
30 or asymptomatic individuals, is essential for the mitigation of community outbreaks.

31 **Methods and Findings**

32 In this study, we analyze Ct values from 1297 SARS-CoV-2 positive patient saliva samples
33 collected at the Clemson University testing lab in Upstate South Carolina. Samples were
34 identified as positive using RT-qPCR, and clade information was determined via whole genome
35 sequencing at nearby commercial labs. We also obtained patient-reported information on
36 symptoms and exposures at the time of testing. The lowest Ct values were observed among
37 those infected with Delta (median: 22.61, IQR: 16.72-28.51), followed by Alpha (23.93, 18.36-
38 28.49), Gamma (24.74, 18.84-30.64), and the more historic clade 20G (25.21, 20.50-29.916).
39 There was a statistically significant difference in Ct value between Delta and all other clades (all
40 $p_{adj} < 0.01$), as well as between Alpha and 20G ($p_{adj} < 0.05$). Additionally, pre- or asymptomatic
41 patients ($n=1093$) showed the same statistical differences between Delta and all other clades
42 (all $p_{adj} < 0.01$); however, symptomatic patients ($n=167$) did not show any significant differences
43 between clades. Our weekly testing strategy ensures that cases are caught earlier in the
44 infection cycle, often before symptoms are present, reducing this sample size in our population.

45 **Conclusions**

46 COVID-19 variants Alpha and Delta have substantially higher viral loads in saliva compared to
47 more historic clades. This trend is especially observed in individuals who are pre- or
48 asymptomatic, which provides evidence to the high transmissibility and rapid spread of
49 emerging variants. Understanding the viral load of variants spreading within a community can
50 inform public policy and clinical decision making.

51

52

53 **Introduction:**

54 The United States confirmed its first positive SARS-CoV-2 case on January 21, 2020 [1].
55 As of December 1, 2021, there have been over 265 million cases globally and 48 million in the
56 United States alone. Most recently, clade 21A, classified as the Delta variant, spread rapidly
57 across the globe. On May 29, 2021, the CDC reported that 7.3% of new cases in the U.S.A.
58 were identified as Delta, and 65.4% of cases were clade 20I (Alpha). By August 28, 99.1% of
59 reported cases were Delta [1]. This rapid shift may be attributed to key mutations that increase
60 transmissibility due in part to a higher viral load.

61 In early 2021, the Alpha variant spread rapidly due to the N501Y mutation in the S
62 protein which enhances its affinity for ACE2. The Delta variant lacks this mutation but carries
63 several mutations within the S protein; specifically, L452R, T478K, and P681R, which confer
64 resistance to monoclonal antibody treatments [2]. The L452R and T478K mutations may also
65 increase transmissibility of the virus by stabilizing the ACE2-RBD complex [2]. Another mutation
66 within the N protein, R203M, increases viral mRNA delivery and expression and facilitates the
67 Delta variant to produce >50-fold more viral particles [3]. These mutations may improve host cell
68 binding affinity, as well as increase viral production, and may contribute to the rapid global
69 spread of this variant.

70 Most studies of SARS-CoV-2 viral loads used the nasopharyngeal (NP) swab sample
71 collection method [4-6]. While effective at diagnosing infection, there is little evidence that RT-
72 qPCR cycle threshold (Ct) values from these samples are correlated to viral load, and thereby,
73 virus transmissibility. The amount of viral RNA collected by NP swabs may vary in each sample,
74 and therefore, serves as a poor viral load indicator. Alternatively, the viral load in saliva samples
75 has been well correlated with COVID-19 symptoms and transmissibility [7,8]. Low Ct values are
76 associated with high viral load and increased transmissibility [9]. This correlation is primarily due
77 to viral presence in saliva droplets that facilitate spread when infected individuals are in

78 proximity. Saliva has been shown to be an accurate diagnostic tool, yielding comparable Ct
79 values to NP swabs while decreasing both discomfort to patients and risk of transmission to
80 healthcare workers during collection [10].

81 **Methods:**

82 Ethical review for this study was obtained by the Institutional Review Board of Clemson
83 University. This is a retrospective study on archived deidentified samples and data. The
84 samples and data sets were striped of patient identifiers prior to any SARS-CoV2 sequencing
85 and data analysis. To evaluate the relative viral load of the variants of concern (VOC) found in
86 upstate South Carolina (Alpha, Gamma, and Delta), we compared the Ct values from saliva
87 samples from the SARS-CoV-2 testing lab at Clemson University, which also provides free
88 testing for the surrounding community [11]. University surveillance testing is mandatory for
89 students and employees on a weekly or bi-weekly schedule regardless of vaccination status
90 [12]. The study population includes all university students and employees, as well as members
91 of the surrounding community that tested positive between January and November 2021.
92 Samples were labeled as “symptomatic” if the patient self-reported symptoms at the time of
93 collection, or “exposed” if they reported recent viral exposure. All other samples were
94 considered “surveillance”. Only one positive test was included for each patient; any subsequent
95 tests were excluded from our analysis.

96 SARS-CoV-2 positive saliva samples were identified using the TigerSaliva RT-qPCR
97 testing method, which targets the N gene [11]. Positive controls made from synthetic RNA at
98 200 viral copies/ μ L resulted in a Ct value of approximately 24. It was also determined that a Ct
99 of 33 was equivalent to 1 viral copy/ μ L, and as such any samples with a Ct lower than 33 were
100 considered positive. Samples were run in duplicate, and the average Ct value from both
101 replicates was used for this analysis.


102 Heat treated saliva samples were commercially sequenced (Premier Medical Sciences,
103 Greenville, SC; Labcorp, Durham, NC) using the ARTIC protocol. Briefly, RNA was extracted

104 from saliva samples via MagBind Viral RNA Kit (Omega Biotek, Norcross, GA) and recovered
105 SARS-CoV-2 RNA quantity was assessed via Logix Smart COVID-19 assay (Co-Diagnostics,
106 Salt Lake City, UT). Samples with sufficient RNA quantity were sequenced on the Illumina
107 platform using NovaSeq 6000 or NextSeq500/550 flow cell. Sequences were assembled and
108 analyzed using nf-core/viralrecon v.2.2 [13]. Sequence data was uploaded to SC DHEC,
109 GenBank, and GISAID (see Supplementary Data). Some samples had ambiguous regions that
110 prevented database uploads, but all had sufficient information to confidently assign clade by
111 Pangolin and Nexclade.

112 Ct values among VOCs were compared: 20I (Alpha), 21A (Delta), 20G, and 20J
113 (Gamma, V3) [14]. Due to low prevalence in the Upstate SC community, 20H (Beta) samples
114 (n=8) were excluded from analysis. To maintain phylogenetic independence, we only compare
115 Ct values for variants at branch tips within the NextClade phylogeny [15].

116 **Results and Discussion:**

117 We first determined the clade composition in our community from the sequenced
118 positive samples between January and December 2021 (Fig 1). From January to July, we
119 sequenced all positive samples stored from the lab. Due to the increase in positive samples
120 during the Delta surge, we sequenced a statistical sampling of positives (approximately 15%) to
121 ensure accurate coverage of our community demographics.




122

123 **Fig 1. Clade composition of samples run in the REDDI Lab from January to December**

124 **2021.** Clade determination was made via whole genome sequencing. There were few positive
125 samples between May and June 2021 due to the university summer break.

126

127 To compare Ct values, and thereby infectious potential, statistical analyses were
128 performed in an R environment using Kruskal-Wallis test followed by Dunn's test of multiple
129 comparisons (Fig 2). SARS-CoV-2 positive samples showed a significant difference between
130 Delta (median: 22.61, IQR: 16.72-28.51) and all other clades [Alpha: 23.93 (18.36-28.49),
131 Gamma: 24.74 (18.84-30.64), 20G: 25.21 (20.50-29.916)]. When only surveillance samples
132 were considered (Fig 2B), the same trend was observed with Delta (median: 22.56, IQR: 16.67-
133 28.45) having a significantly lower median Ct from other clades [Alpha: 23.81 (18.51-29.11),
134 Gamma: 24.69 (18.84-30.54), 20G: 25.75 (21.53-29.98)]. Additionally, both groups showed a
135 significant difference in Ct values between Alpha and 20G.



136

137

138

139

140

141

142

143

144

145


146

147

Figure 2: N1 Ct values of common clades in saliva. We analyzed the Ct values from a total of 1297 SARS-CoV-2 positive saliva samples, using the N gene target. **2A: Comparison of all samples.** Delta (n=787) showed a statistically significant difference in Ct value when compared to 20G (n=159), Alpha (n=258), and Gamma (n=87). **2B: Comparison of surveillance samples.** When only surveillance samples were considered, the same trends were observed, showing a significant difference between Delta (n=691) and all other clades (20G: n=95, Alpha: n=181, Gamma: n=86). Both groups also showed a significant difference when comparing Alpha and 20G. **2C. Comparison of symptomatic samples.** There were no significant differences in Ct values observed among symptomatic samples for Delta (n=70), Alpha (n=58), Gamma (n=1), and 20G (n = 39). *p.adj<0.05, **p.adj<0.01, ***p.adj<0.001, ****p.adj<0.0001.

148 When analyzing only symptomatic samples, we found no statistically significant
149 difference in Ct values amongst the clades (Fig 2C). The benefit of Clemson University's
150 surveillance strategy is that infections are caught early, often before symptoms are present,
151 which decreases the number of symptomatic samples in our population. While there are
152 significant differences in viral loads between the VOC clades and 20G in pre-symptomatic and
153 asymptomatic patients at the time of initial diagnosis, this trend is not necessarily maintained as
154 the disease progresses. This may explain the discordant results in the literature; studies which
155 primarily focused on tests from COVID-19 hospitalized patients did not observe differences in
156 viral loads among the clades [6], whereas studies that included tests from earlier stage
157 diagnoses observed significant differences in viral loads, particularly for Delta [4,5].

158 Additionally, patients that report symptoms are much more likely to test positive
159 compared to non-symptomatic patients (Fig 3). From January to November 2021, the average
160 positivity rate for symptomatic samples was 12.71% and for surveillance samples was 0.98%.
161 During the surge in cases due to the Alpha variant in March 2021, samples from patients at the
162 community site who reported exposure were much more likely to be positive for SARS-CoV-2
163 when compared to non-exposed (8.8% vs 1.7%). However, after the emergence of Delta, the
164 test positivity rate was 10% in both groups. This is likely due to the overwhelming presence of
165 Delta within our community and the extremely high viral load, likely ensuring that everyone had
166 some level of exposure.



167

168 **Fig 3: Number of tests and positive tests per category, by week.** Note that the y-axis is on a
169 log₁₀ scale. Samples are labeled “symptomatic” if the patient reports symptoms at the time of
170 testing, or labeled “exposed” if they report exposure to a positive patient. Surveillance samples
171 represent the rest of the samples collected. The lower case load during week 11 is due to the
172 university’s spring break, and weeks 18-29 account for summer break.

173

174 Due to a non-normal data distribution, we performed Kruskal-Wallis test for stochastic
175 dominance. However, it has been suggested that ANOVA is robust to slight non-normality [16].
176 Reanalyzing the data with Welch’s ANOVA, we observed similar results (SFig 1) and
177 determined there was approximately an 8-fold difference in viral load between Delta and 20G,
178 which is consistent with other studies using NP swabs from initial diagnostic samples [4,5]. Our
179 results highlight the significant difference in Ct values between Delta samples and other VOCs.

180 **Conclusion:**

181 Overall, our study showcases the increased viral load of the Delta variant and provides
182 evidence for its rapid global spread. A major benefit to saliva-based testing is the ease of
183 testing; people are more inclined to test frequently. Specifically, our data show that the Delta
184 VOC has a higher viral load in saliva even in healthy, young individuals who are pre- or
185 asymptomatic. These individuals are not often captured by other studies as they are not likely to
186 seek out testing; however, they are known to contribute to the rapid spread of COVID-19 [17].
187 High infectivity of new variants necessitates accurate surveillance. It is expected that future
188 dominant strains, like the newly emerging Omicron, will have viral loads comparable to or
189 greater than Delta to achieve a competitive advantage.

190

191 **Funding:**

192 This work is supported by the National Institutes for Health [P20GM121342], Clemson
193 University's Vice President for Research, and the South Carolina Governor & Joint Bond
194 Review Committee.

195

196 **Acknowledgements:**

197 The authors thank Clemson University's administration, medical staff, and the REDDI Lab who
198 helped develop and implement SARS-CoV-2 testing. Thank you to Mayor Robert Halfacre and
199 Dr. Ted Swann for facilitating Clemson community testing. We thank Dr. Vidhya Narayanan, Dr.
200 David Elms, and Russ Nuttall for technical assistance of whole genome sequencing. Thank you
201 to Kaitlyn Williams, Rachel Ham, Sujata Srikanth, and Jeremiah Carpenter for sample
202 preparation. We thank the REDDI Lab clinical director, Dr. Michael Friez, technical supervisor,
203 Dr. Congyue Peng, and clinical supervisors Lauren Cascio and Wael Namouz for maintaining
204 high complexity certification standards (CLIA number 42D2193465). We thank Rachel Ham and
205 Austin Smothers for their critical reading of this manuscript.

206

207 **Potential Conflicts of Interest:** All authors: no reported conflicts of interest or competing
208 interests.

209

210 **Data accessibility:** All relevant data are within the manuscript and its Supporting Information
211 files. Data analysis scripts can be found at [https://github.com/CUGBF/SARS-CoV-2_Ct-vs-](https://github.com/CUGBF/SARS-CoV-2_Ct-vs-Clade.git)
212 [Clade.git](https://github.com/CUGBF/SARS-CoV-2_Ct-vs-Clade.git)


213

214 **References:**

- 215
- 216 1. Center for Disease Control. COVID Data Tracker. Available at
217 <https://covid.cdc.gov/covid-data-tracker/#datatracker-home>. Accessed 2 December
218 2021.
- 219 2. Cherian, S, Potdar, V, Jadhav, S, *et al.* SARS-CoV-2 Spike Mutations, L452R, T478K,
220 E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India.
221 *Microorganisms*, **2021**; 9(7), 1542.
- 222 3. Syed, AM, Taha, TY, Tabata, T, *et al.* Rapid assessment of SARS-CoV-2 evolved
223 variants using virus-like particles. *Science (New York, N.Y.)*, **2021**; eabl6184. Advance
224 online publication.
- 225 4. Teyssou, E, Delagrèverie, H, Visseaux, B, *et al.* The Delta SARS-CoV-2 variant has a
226 higher viral load than the Beta and the historical variants in nasopharyngeal samples
227 from newly diagnosed COVID-19 patients. *Journal of Infection*, **2021**;83(4), e1–e3.
- 228 5. Wang, Y, Chen, R, Hu, F, *et al.* Transmission, viral kinetics and clinical characteristics of
229 the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. *Eclinicalmedicine*, **2021**;
230 40, 101129.
- 231 6. Tani-Sassa, C, Iwasaki, Y, Ichimura, N, *et al.* Viral loads and profile of the patients
232 infected with SARS-CoV-2 Delta, Alpha, or R.1 variants in Tokyo. *Journal of Medical*
233 *Virology*, **2021**; 10.1002/jmv.27479.
- 234 7. Huang, N, Pérez, P, Kato, T, *et al.* SARS-CoV-2 infection of the oral cavity and saliva.
235 *Nat Med*, **2021**; 27, 892–903.
- 236 8. Sarkar B, Sinha RN, Sarkar K. Initial Viral Load of a COVID-19-Infected Case Indicated
237 by its Cycle Threshold Value of Polymerase Chain Reaction Could be used as a
238 Predictor of its Transmissibility - An Experience from Gujarat, India. *Indian J Community*
239 *Med*. **2020**; 45(3):278-282.
- 240 9. Jefferson, T, Spencer, EA, Brassey, J, Heneghan, C. Viral Cultures for Coronavirus
241 Disease 2019 Infectivity Assessment: A Systematic Review. *Clinical Infectious Diseases*,
242 **2021**; 73(11), e3884–e3899.
- 243 10. Yokota, I, Hattori, T, Shane, PY, *et al.* Equivalent SARS-CoV-2 viral loads by PCR
244 between nasopharyngeal swab and saliva in symptomatic patients. *Sci Rep*, **2021**; 11,
245 4500.
- 246 11. Ham, R. E., Smothers, A. R., King, K. L., Napalitano, J. M., Swann, T. J., Pekarek, L. G.,
247 Blenner, M. A., Dean, D. Efficient SARS-CoV-2 Quantitative Reverse Transcriptase PCR
248 Saliva Diagnostic Strategy utilizing Open-Source Pipetting Robots. *J. Vis. Exp.* (Pending
249 Publication), e63395, In-press (2022).
- 250 12. Rennert, L, McMahan, C, Kalbaugh, CA, *et al.* Surveillance-based informative testing for
251 detection and containment of SARS-CoV-2 outbreaks on a public university campus: an
252 observational and modelling study. *The Lancet. Child & Adolescent Health*, **2021**; 5(6),
253 428–436.
- 254 13. Patel, H, Varona, S, Monzón, S, *et al.* nf-core/viralrecon: nf-core/viralrecon v2.2 - Tin
255 Turtle (2.2) **2021**. Zenodo.
- 256 14. https://github.com/CUGBF/SARS-CoV-2_Ct-vs-Clade
- 257 15. Aksamentov, I, Roemer, C, Hodcroft, EB, Neher, RA. Nextclade: clade assignment,
258 mutation calling and quality control for viral genomes. *Journal of Open Source Software*,
259 **2021**; 6(67), 3773.
- 260 16. Blanca, MJ., Alarcón, R, Arnau, J, Bono, R., & Bendayan, R. Non-normal data: Is
261 ANOVA still a valid option?. *Psicothema*, **2021**; 29(4), 552–557.
- 262 17. Johansson, MA, Quandelacy, TM, Kada, S, *et al.* SARS-CoV-2 Transmission From
263 People Without COVID-19 Symptoms. *JAMA Network Open*, **2021**; 4(1), e2035057.

264 **Supporting Information:**

265



266

267 **SFig 1: Analysis of Ct values using Welch's ANOVA test. 1A: Comparison of all samples.**

268 We observed a statistically significant difference between Delta and all other clades, including

269 an 8-fold difference in viral load when compared to 20G. **1B: Comparison of only surveillance**

270 **samples.** The same difference in median Ct was observed between Delta and all other clades.

271 Additionally, surveillance samples showed a statistical difference between Alpha and 20G.

272 *p.adj<0.05, **p.adj<0.01, ***p.adj<0.001, ****p.adj<0.0001

273

274 **SFile 1: Accession numbers for sequenced samples uploaded to SCDHEC, GenBank, and**


275 **GISAID.**

276




277

278


Number of Sequenced Samples




- 19A
- 19B
- 20A
- 20B
- 20C
- 20G
- 20H (Beta, V2)
- 20I (Alpha, V1)
- 20J (Gamma, V3)
- 21A (Delta)
- 21B (Kappa)
- 21C (Epsilon)
- 21D (Eta)
- 21F (Iota)




SYMPTOMATIC



EXPOSED



SURVEILLANCE



■ Total Number of Tests
 ■ Number of Positive Cases